

File No: BIO/CT/21/000104
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

From:

The Drugs Controller General, India
Directorate General of Health Services,

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated: 11.03.2022

To,

M/s Enzene Biosciences Limited,
Plot No A 22, A/ 1/ 2 Chakan Industrial Area,
Phase 2, Khalumbre, Chakan,
Pune, Maharashtra (India) - 410501

Subject: Application for grant of permission to conduct Phase IV clinical trial titled – “A phase IV, prospective, open label, single-arm, multicentre clinical study to evaluate the safety and efficacy of Teriparatide in patients with postmenopausal osteoporosis” vide Protocol No.:- ALK05-TERI2, Version- 2.1 dated 24.02.2022 - regarding

Ref.: Your Application No. BIO/CT04/FF/2021/27412 dated 12-08-2021

Sir,

With reference to your Application No.: BIO/CT04/FF/2021/27412 dated 12-08-2021, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019. The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

Yours faithfully,

VENUGOPAL
G SOMANI

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA),
serialNumber=112046a34c217270a0b25574b732465d24907365
5e953d9c45558748e3113c, postalCode=110002, st=DELHI,
serialNumber=e97d241aa0c0bba41522525fca0705074b4997e6
02465c68816282ad6af5d, cn=VENUGOPAL G SOMANI
Date: 2022.03.11 18:18:24 +05'30'

(Dr. V. G. Somani)
Central Licensing Authority

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s Enzene Biosciences Limited, Plot No A 22, A/ 1/ 2 Chakan Industrial Area, Phase 2, Khalumbre, Chakan, Pune, Maharashtra (India) - 410501 to conduct clinical trial of the new drug or investigational new drug as per Protocol No.:- Protocol No.:- ALK05-TER12, Version- 2.1 dated 24.02.2022 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

**VENUGOPAL
G SOMANI**

Digitally signed by VENUGOPAL G SOMANI
DN: c=IN, o=CENTRAL DRUGS STANDARD CONTROL
ORGANIZATION, ou=DRUGS CONTROLLER GENERAL (INDIA),
pseudonym=112046a34e21727bacb255748732c456d249073e5
5e953d9cb558740ee3113c, postalCode=110002, st=DELHI,
serialNumber=e97f241aa0c0bba41522525ffca0705074b4997e6
b2f4b5c8d81cf282adeaf5d, cn=VENUGOPAL G SOMANI
Date: 2022.03.11 18:18:57 +05'30'

Place: New Delhi

Date: 11.03.2022

(Dr. V. G. Somani)

Central Licensing Authority

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Teriparatide Injection, I.P. (600mcg/2.4mL), Disposable prefilled pen	
Therapeutic class:	Calcium homeostasis parathyroid hormones	
Dosage form:	Teriparatide Injection 600 mcg/2.4 mL, Disposable Pen with pre-assembled cartridge in a blister card.	
Composition:	Each 1 ml contains-	
	Teriparatide drug substance (IP)	0.250 mg
	Sodium acetate (USP)	0.10 mg
	Acetic acid glacial (I.P, JP, USP, BP/Ph. Eur)	0.41 mg
	D- Mannitol (I.P, BP/Ph.Eur.)	45.4 mg
	m-Cresol (Ph. Eur, USP/NF)	3.0 mg
	Sodium hydroxide (I.P, JP,NF, BP/Ph. Eur)	q.s. to adjust pH to 4.0±0.2
	Hydrochloric acid (I.P, JP, NF, BP/Ph. Eur)	q.s. to adjust pH to 4.0±0.2
	Water for Injection (IP, USP)	qs to 1.0 mL
Indications:	Postmenopausal Osteoporosis	

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Lifepoint Multispecialty hospital, 145/1, Mumbai Bangalore highway, Near Hotel Sayaji, Wakad, Pune- 411057, Maharashtra	LPR Ethics Committee, Lifepoint Multispecialty hospital, 145/1, Mumbai Bangalore highway, Near Hotel Sayaji, Wakad, Pune-411057, Maharashtra EC Reg. No.: ECR/751/Inst/MH/2015/RR-18	Dr. Hrishikesh Patkar
2	Institute Of Medical Sciences, Banaras Hindu University Varanasi-221005 UP	Institutional Ethics Committee, IMS BHU, Varanasi-221005 EC Reg. No.: ECR/526/Inst/UP/2014 /RR-20	Dr. Jitendra Singh

3	Medical College and hospital, MCH building, 4th Floor, 88 College street , Kolkata-700073 West Bengal	Institutional Ethics committee for Human Research, Medical College and hospital, 88 College street, Kolkata -700073 EC Reg. No.: ECR/287Inst/WB/2013/RR-19	Dr. Kaushik Basu
4	Sancheti Institute for Orthopedics and Rehabilitation 16, Shivajinagar, Pune 411005	Institutional Ethics Committee Sancheti Institute for Orthopaedics and Rehabilitation 16, Shivajinagar, Pune 411005 EC Reg. No.: ECR/90/Inst/MH/2013/RR-16	Dr. Parag Sancheti
5	Christian Medical College, Ida Scudder Road, Vellore-632004	Institutional Review Board, Christian Medical College, Bagayam, Vellore EC Reg. No.: ECR/326/Inst/TN/2013	Dr. Thomas Paul
6	King George Hospital, Clinical Research Medicine, Maharanipecta, Visakhapatnam-530002, Andhra Pradesh	Institutional Ethics committee, King George Hospital, Maharanipecta, Collector Office Junction, Visakhapatnam-530002, Andhra Pradesh EC Reg. No.: ECR/197/Inst/KGH/2013/RR20	Dr. Bongji Vivekanand
7	Om Research Center, Om Research Center and maternity Home ,SA 17/3, P-4, Sri Krishna Nagar, Paharia , Ghazipur Road, Varanasi - 221007, Uttar Pradesh	Institutional Ethics committee, Om Research Center, Om Research Center and maternity Home, SA 17/3, P-4, Sri Krishna Nagar, Paharia, Ghazipur Road, Varanasi -221007, Uttar Pradesh EC Reg. No.: ECR/628/INST/UP/2014/RR20	Dr. Shalini Srivastava